Anthem Biosciences Q1 FY27: Soft Revenue Quarter, But Margins Hold Firm

Anthem Biosciences reported a softer start to FY27, with consolidated revenue from operations at INR 4,182 million (about 418.2 crore) for the quarter ended June 30, 2026. Revenue declined 22.6% year on year and 31.5% sequentially. Management attributed the decline to timing shifts in deliveries to key customers, while reiterating that underlying demand remains strong and a higher concentration of scheduled deliveries is expected in the latter half of the year.

Even with the top-line drop, profitability stayed resilient. Consolidated EBITDA came in at INR 1,755 million (175.5 crore), with an EBITDA margin of 39.6%, up 153 basis points year on year. Profit after tax was INR 1,199 million (119.9 crore), translating to a PAT margin of 27.1%, also higher than the prior year quarter.

Segment performance: CRDMO remains dominant

The quarterly mix continued to be led by the CRDMO business, which delivered INR 3,408 million (340.8 crore), accounting for 81.5% of revenue from operations. Specialty Ingredients contributed INR 774 million (77.4 crore), or 18.5%.

Management highlighted that the soft quarter was a function of customer delivery schedules rather than demand weakness. In the earnings call, leadership repeatedly cautioned investors against treating any single quarter as a benchmark, emphasizing that the CRDMO model naturally has quarter-to-quarter lumpiness depending on customer inventory movements, market launches, and regulatory timelines.

Note: The company reported EBITDA including other income. Other income in Q1 FY27 was INR 249 million.

Operations and capacity: utilization details and ramp-up signals

The call provided useful operating datapoints across facilities. The CFO stated Unit 1 custom synthesis utilization was around 78% in Q1 FY27 (similar to 74% at FY26 end). Unit 2, which saw meaningful capacity addition last year, ran at about 50% utilization for custom synthesis during the quarter, and fermentation utilization was also about 50% across the installed 140 kiloliters.

NeoAnthem (Unit 3) showed a clearer ramp-up, with utilization in Q1 FY27 at about 30% to 35%, up from roughly 15% in FY26. The CEO clarified this increase is mostly driven by new projects rather than merely shifting existing production, supported by capabilities such as a modern pilot plant, peptide synthesis, and oncology manufacturing.

Management also indicated that utilization should improve across subsequent quarters as deferred deliveries move into Q2, Q3, and Q4.

Capex and expansion: Unit 4 becomes the medium-term growth lever

A key strategic theme is the ongoing Unit 4 project. Management reiterated the Unit 4 Phase 1 capex outlay at around INR 1,200 crore, spread roughly 50-50 across FY27 and FY28. The timeline shared was readiness by the end of FY28. Phase 1 is planned to add 365 kiloliters of custom synthesis capacity and 100 kiloliters of fermentation capacity, and management also mentioned adding a food and nutra plant at the site.

For FY27, the CFO guided total capex at around INR 700 crore. He also noted capex would remain elevated in FY28 because of Unit 4, and should come down thereafter.

The investment program is backed by a strong balance sheet. Net cash as of June 30, 2026 stood at INR 17,197 million (1,719.7 crore), materially higher than INR 7,848 million as of June 30, 2025.

Commercial pipeline, customer additions, and GLP-1 commentary

On pipeline visibility, management stated it had about 60% order book visibility for full-year delivery and said that even after Q1 it continued to stand at around 60% due to replenishment. Management clarified that the order book concept is largely relevant for CRDMO, where raw material procurement and manufacturing lead times require orders in advance.

The CEO mentioned onboarding one new Big Pharma customer, describing it as a potentially meaningful relationship. However, he also said the agreement had not yet been signed and could take time to close, though he expects traction in later quarters of FY27. The relationship was described as multi-dimensional, spanning R and D, new projects, and certain products where the customer seeks to diversify supply chains.

On GLP-1, management addressed questions on Semaglutide API. The CEO stated that commercial supply has not begun and the company is awaiting CDSCO approval. He said the company has completed trials and scale-up work, sampled several large customers, and expects the approval in a quarter or two. Management also stated it is not targeting other markets at the moment, though overseas sampling and conversations have started, with India approval seen as the first gate.

Margin resilience: cost discipline and technology positioning

The company highlighted year-on-year improvement in EBITDA and PAT margins. Management attributed this to cost efficiencies, yield optimization, and employee productivity. The CEO also linked longer-term margin sustainability to technology adoption such as flow chemistry and biocatalysis, stating these tools help cut cost of goods and allow the company to engage customers beyond pure execution.

On the call, the CFO said other expenses were broadly in line with historical trends and not driven by one-offs. He also guided that employee cost as a percentage of sales looks higher in Q1 due to muted revenue, but on a full-year basis should be around 13%.

What to track from here

Anthem Biosciences framed Q1 FY27 as a timing-driven soft quarter, not a change in the medium-term business trajectory. Management expects delivery schedules to normalize in the coming quarters, supported by order book visibility, improving utilization, and ongoing customer additions.

The key near-term monitorables will be the pace of recovery in CRDMO revenues through Q2 to Q4, utilization improvement at Unit 2 and fermentation, and progress on Unit 4 execution. Separately, Semaglutide API remains an optional upside once CDSCO approval is received, but management made it clear it has not yet started contributing to sales.

Overall, the quarter reinforced a familiar theme for CRDMO businesses: revenues can be lumpy, but operating discipline and a strong balance sheet can cushion volatility while capacity expansion sets up the next phase of growth.